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INTERMEDIATE-RISK PROSTATE CANCER, ANDROGEN 
DEPRIVATION THERAPY AND THE RISK OF DEATH 
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Purpose: Intermediate-risk prostate cancer comprises a 
heterogenous group, whose management includes external 
radiation (EBRT), brachytherapy (brachy), or surgery. Androgen 
deprivation therapy (ADT) has been shown to improve survival in 
IR prostate cancer when combined with standard dose EBRT 
(RTOG 9408). Its role with brachy is unclear, but appears to add 
10-15% absolute improvement in biochemical control (as 
presented at CARO 2015). In our practice the use of ADT in this 
context has declined from 91% in 1990 to 21% in 2015, because 
of uncertainty of its role, and concerns of toxicity. The aim of 
this study was to examine the effect of ADT on subsequent 
survival of men treated for IR with brachy. 
Methods and Materials: Men treated for IR prostate cancer 1998-
2011 were prospectively followed in an outcomes database. They 
were risk grouped using the ProCars scheme into low- and high-
IR. Endpoints were biochemical control (bNED, by the Phoenix, 
nadir + 2 definition) and survival. Death information was 
obtained from the provincial cancer registry. Cause of death was 
ascribed to prostate cancer, cardiovascular disease, other cause, 
or unknown. bNED and survival were calculated using the Kaplan-
Meier method with log-rank statistics, and multivariable analysis 
performed.  
Results: 2232 men form the study cohort. Eighty-seven percent 
had low-IR cancer, and 13% high-IR. Six months of neoadjuvant 
and concurrent ADT was used in 50%. Ninety-nine percent 
received 125I low dose rate permanent brachytherapy 
monotherapy (144 Gy) and 1% received 115 Gy plus pelvic EBRT, 
(46 Gy). Median follow up for bNED is five years (range 0-17) and 
for survival seven years (4-17, with 23% followed for more than 
10 years). Actuarial biochemical control at 10 years is 74% 
without, and 88% with ADT (p < 0.001), and both low-IR (77% 
versus 86%) and high-IR (68% versus 83% at six years) show this 
improvement. Overall survival is 89% without ADT and 85% with 
ADT at 10 years (p = 0.041). Cardiovascular deaths were 
significantly increased with ADT (5% versus 2.3% at 10 years, p = 
0.015), and contribute to the decreased overall survival 
observed. Prostate cancer deaths occurred in 0.5% and 1.5% 
without and with ADT, at 10 years. Multivariable analysis shows 
that the excess cardiac deaths are due to comorbidity and age. 
Conclusions: Although bNED is improved by the addition of six 
months of ADT, overall survival is worse when examined in a 
mature dataset. This detriment is due to excess non-prostate 
causes, including cardiovascular deaths. The main drivers of the 
latter appear to be presence of cardiac risk factors, other 
comorbidity, and age. The use of ADT may be a particular 
concern in patients with such risk factors. Benefits, risks, and 
patient preference should be considered when determining the 
addition of ADT with BT for IR prostate cancer. 
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Purpose: Brachytherapy is an integral component of radiation 
treatment of gynecological malignancies. Many locally-advanced 
pelvic tumours may not be adequately controlled with 
intracavitary techniques due to challenges in dose conformality. 
ISBT can improve dosimetry through the insertion of catheter 
needles directly into tumour tissue. However, due to its 
invasiveness and potential risks of complications, there is a lack 
of expertise in ISBT. The goal is to evaluate the safety of ISBT by 
studying the acute complications with a perineal applicator 
technique. 
Methods and Materials: Thirty-nine patients at a single 
institution treated with high-dose rate perineal ISBT from 
September 2014 to January 2016 were included in a prospective 
registry trial. Median age was 65 (range 23-88) with 13 cervical 
cancer patients, 11 vaginal, 11 recurrent endometrial, one 
vulvar. Three patients were treated palliatively. No bowel 
preparation was used prior to implant and no antibiotics were 
given perioperatively. Post-procedure, patients were imaged 
with CT or MRI with no attempt to adjust needle depth or position 
after review of imaging. First follow up visit occurred within 6 
weeks after treatment and then 2-3 months later. Post-operative 
adverse events were graded with CTCAE V3.0 and radiation 
related toxicity with RTOG common criteria.  
Results: Median follow up time was three months. Thirty-four 
patients were initially treated with external beam radiation 
therapy to the pelvis with a dose of 45 Gy (median). A total of 
56 implants were performed; 22 patients received one implant 
while 17 had two. Median hospital stay was two days (1-5). The 
median number of needles for each implantation was 17 (8-26). 
The most commonly invaded organ by the interstitial catheters 
was the bladder (13) followed by bowel (10) and rectum (nine). 
Eighteen patients had radiological evidence of needle intrusion 
to a pelvic organ and six patients had more than one pelvic organ 
punctured by the catheters. Two acute organ complications 
attributable to needle intrusion to the bladder were found. One 
patient developed G1 hematuria and was discharged without 
delay and another had G2 hematuria requiring manual saline 
irrigation. No GI complications were found. Three patients 
developed perineal cellulitis post-ISBT. Acute radiation-related 
toxicities were seen in six patients with Grade 1 GI and/or GU. 
Conclusions: ISBT is a safe and feasible treatment for locally-
advanced gynecological cancers. With no attempted post-
treatment adjustment, radiological evidence of needle intrusion 
into pelvic organs is a common finding. No severe organ 
complications were found and the rate of acute complications 
are low. Vulva and perineal infection post-ISBT was the most 
common complication related to needle implantation. The 
development of real-time image-guidance may improve implant 
positioning for tumour coverage but likely will not affect the 
existing low rate of acute organ complications. 
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Purpose: To compare results of radical prostatectomy (RP) and 
permanent seed prostate brachytherapy (PB) is difficult because 
of different definitions for recurrence and differences in baseline 
characteristics. We analyzed treatment results of both 
treatments in low- and low-intermediate prostate cancer 
patients from a single tertiary centre using similar definitions for 
biochemical recurrence. 
Methods and Materials: Patients were selected from each 
department’s internal database based on pre-operative selection 
criteria from NCCN guidelines (2015) for low- and low-
intermediate-risk patients. All selected patients had complete 
data on Gleason score, clinical staging and pre-treatment 
prostate specific antigen (PSA) value and none had received any 
neo-adjuvant androgen deprivation therapy. The end point was 
biochemical recurrence (BCR) or any salvage treatment for both 
RP and PB at 48 (± 4) months after treatment. The biochemical 
relapse threshold was set at PSA ≥ 0.5ng/mL for PB and two PSA 
values ≥ 0.2 ng/mL for RP. Patients from both treatment groups 
were compared using non-parametric tests. A binary logistic 
regression analysis was done to test an association of treatment 
and pre-treatment factors with a BCR at 48 months. 
